TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven relapsed or refractory non-Hodgkin's lymphoma~* Scheduled to undergo high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan) with autologous peripheral blood mononuclear cell transplantation~* No metastatic disease involving the bone marrow~PATIENT CHARACTERISTICS:~Age:~* 17 to 65~Performance status:~* ECOG 0 or 1~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* No active hepatitis B or C~* Bilirubin less than 2.5 times normal\*~* SGOT or SGPT less than 2.5 times normal\*~* Alkaline phosphatase less than 2.5 times normal NOTE: \* Unless Gilbert's syndrome present~Renal:~* Creatinine clearance greater than 50 mL/min~Cardiovascular:~* Cardiac ejection fraction normal~Pulmonary:~* DLCO at least 50% predicted~* FEV_1 and FVC at least 75% predicted~Other:~* HIV negative~* Not pregnant~* Negative pregnancy test~* No non-neoplastic disease that would preclude intensive chemotherapy~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior external beam radiotherapy to more than 25% of the active bone marrow~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
ELIGIBILITY~Pre-registration inclusion:~Must be at least 18 years of age and capable of giving informed consent.~High risk breast cancer defined as the following:~* stage IV breast cancer~* inflammatory breast carcinoma~* Stage II breast cancer with more than 10 positive axillary lymph nodes~* Stage IIIA breast cancer (tumor greater than or equal to 5 cm with at least one positive axillary lymph note)~A minimum of 3 grams of non-necrotic, resectable breast cancer.~ECOG Performance Score (PS) less than (\<3.0).~Pre-registration exclusion:~* ECOG Performance Score (PS) greater than or equal to 3.0.~* Congenital or acquired immunodeficiency including infection with human immunodeficiency virus.~* Significant behavioral or psychological problems that preclude adequate informed consent or follow-up.~Registration inclusion:~* Major clinical responses defined as either Complete response (CR) by conventional staging work-up such as CT scan and bone scan.~Or Stable partial response (PR) defined as more than 50% tumor reduction which remains stable by serial CT scans or bone scans over a 3-month span.~* More than 60 micrograms of HSP70 purified.~* ECOG Performance Score(PS) less than 3.0.~* Greater than or equal to 4 weeks post cytotoxic therapy.~Registration exclusion:~* ECOG Performance Score(PS) greater than or equal to 3.0.~* Purification of HSP70 is unsuccessful qualitatively or quantitatively.~* On other investigational therapy for breast cancer.~* Positive serum or urine pregnancy test.~* Impaired renal function (serum creatinine \> 2.0) and hepatic function (bilirubin more than 2.0 x and transaminase more than 4.0 x of the upper normal limit).~* Significant active infection requiring hospitalization;~* Acquired immunodeficiency or active autoimmune diseases.~* Significant behavioral or psychological problems that prevent adequate follow-up.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-childbearing female subjects (SAD/MAD) and male and non-childbearing female patients with mild asthma;~* Healthy subjects as determined by past medical history, vitals, physical examination and 12-lead ECG, clinical laboratory tests.~* Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive, weight ≥50 kg;~* Non-smokers or ex-smokers~* Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the subject; able to comply with protocol requirements and or study procedure;~* Negative screen for drugs of abuse and alcohol at screening and on admission.~* Male subjects should agree not to donate sperm for 3 months post dose; and~* Female partners (of child bearing potential) of male subjects should use 2 methods of highly effective contraception for 3 months post last~Additionally for POC~* Pre- bronchodilator Forced expiratory volume in 1 sec( FEV1) of \> 70% (adjusted for age, sex and race)~* Steroid naïve subjects with history of mild asthma that satisfy the Global Initiative for Asthma (GINA) definition of asthma, but otherwise healthy.~Exclusion Criteria:~* Subjects with evidence or history of clinically significant medical history.~* History of tuberculosis (TB) and/or a positive Tuberculin Skin Test and/or QuantiFeron- TB®-Gold test.~* Use of any immunotherapy within 3 months prior to screening.~* History of serious adverse reaction, severe hypersensitivity or allergy to any drug/drug substance (except house dust mite, pollen allergens or cat dander allergy in asthmatics) or in any other circumstance (e.g. anaphylaxis);~* Abnormal liver function~* Positive screen on hepatitis-B surface antigen (HBsAg), antibodies to the hepatitis C (HCV) or antibodies to the human immunodeficiency virus (HIV) 1,2;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RP3128 (Type: EXPERIMENTAL): RP3128, A CRAC channel modulator
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tissue Adhesive vs. Sterile Strips After Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing Pfannenstiel Cesarean delivery~Exclusion Criteria:~* Inability to provide informed consent in English~* Planned use of staples for skin closure~* Unavailability of research personnel to accomplish consent and randomization at the time of cesarean

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tissue Adhesive (Type: EXPERIMENTAL): Tissue Adhesive will be placed over subcuticular suture closure.
- Steri-Strips (Type: ACTIVE_COMPARATOR): Sterile strips will be placed over subcuticular suture closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving selective dorsal rhizotomy (SDR)~* Willingness to Participate~Exclusion Criteria:~* Known Morphine Allergy~* Inability to speak and read the English language

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- DepoDur80 (Type: EXPERIMENTAL): DepoDur will be administered at 80μg/kg (not to exceed 5 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
- DepoDur120 (Type: EXPERIMENTAL): DepoDur will be administered at 120μg/kg (not to exceed 10 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
- Control (Type: PLACEBO_COMPARATOR): Preservative-free normal saline (2.5ml) will be placed in the L1 laminectomy defect and also dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter prior to wound closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Post Market Evaluation of Acessa With TAG

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Women who:~* Are planning to undergo the Acessa procedure~* Are willing and able to comply with all procedures~* Are capable of providing informed consent~Exclusion Criteria: Women who:~* In the medical judgement of the investigator should not participate in this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Acessa Procedure w/o TAG (Type: OTHER): Acessa Procedure without the use of Targeting Animation Guidance
- Acessa Procedure with TAG (Type: OTHER): Acessa Procedure with Targeting Animation Guidance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven lung cancer~* Inoperable~* Non-Small Cell Cancer~* Partial or total bronchial obstruction responsible for functional signs~* T1 to T4, N0-N3, M0-M1~* Patients with functional signs: hemoptysis, infection, cough and, above all, dyspnea~* Contralateral metastases not representing a contraindication insofar as they do not represent a risk of impairment of respiratory function during treatment~* The Karnofsky index should be greater than or equal to 40~* Patients should agree to and tolerate repeated bronchial endoscopy (a disadvantage of all endoscopic treatments)~* Male or female patients aged over 18 years, female patients should not be pregnant (menopause or contraception)~* Patients should have given their written consent to take part in the study~Exclusion Criteria:~* Tracheal lesions and lesions affecting the carina tracheae~* Patients with painful bone metastases (not an absolute criterion since the extent of dyspnea is the decisive element)~* Patients with brain metastases~* Patients having undergone pneumonectomy~* Patients undergoing chemotherapy or radiotherapy or having undergone chemotherapy less than 4 weeks before the procedure or radiotherapy less than 4 weeks before the procedure~* Patients with risk of large vessel erosion or perforation resulting from lesion topography~* In case of allergy to the photosensitizer~* Leukopenia (WBC\<2000), Thrombocytopenia (\< 100 000), PT \> 1.5 normal, Fibrinogen \< 2g/l, a PTT \> 1.5 ULN (Upper Limit of Normal)~* Renal insufficiency~* Hepatic insufficiency~* Patients having already received 70 Gy on the lesion~* Existing tracheoesophageal or bronchoesophageal fistula~* Emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WST11 (Type: EXPERIMENTAL): Treatment with WST11-mediated VTP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Closed-loop Fluid Administration System: Pilot Study to Evaluate Feasibility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients aged 18-75 years~* Scheduled for abdominal surgery under general anesthesia and requiring an invasive arterial blood pressure monitoring~* Consenting to participate in the study~Exclusion Criteria:~* Pregnant, breast feeding women~* Allergy~* Pacemaker~* Psychiatric disease, dementia, brain disease~* Contraindication to hydroxyethyl starch~* Inability to measure pulse pressure variability : arrhythmia, spontaneous breathing, or tidal volume \< 7 ml/Kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Open loop (Type: ACTIVE_COMPARATOR): fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
- Closed-loop (Type: EXPERIMENTAL): Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to freely give written informed consent to participate in the study and have signed the Informed Consent Form;~2. Males or females, age 18 and older at the time of study screening;~3. American Society of Anesthesiologists (ASA) Class I-III (Appendix III) undergoing elective surgery~Exclusion Criteria:~1. Mentally incompetent or unable or unwilling to provide informed consent or comply with study procedures~2. American Society of Anesthesiologists (ASA) Class IV or V; emergency surgeries~3. Children \<18~4. Pregnant patients~5. Patients who have intra-abdominal sepsis or partial or intermittent bowel obstruction or enteritis~6. Patients who are on long term steroids, opioids or antidiarrheals pre operatively~7. Patients who are administered pro kinetics eg. Metoclopramide~8. Patients with recurrent disease in their small bowel - Crohn's disease, or previous irradiated pelvis resulting in irradiation bowel disease~9. End ileostomies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): None
- Therapeutic (Type: EXPERIMENTAL): Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-44 years~* Must be biologically female (defined as sex at birth)~* HIV negative women with at least one of the following risk factors in the past 5 years~  1. Injection drug use or use of crack, cocaine, heroin, or methamphetamine~ 2. Diagnosed with a sexually transmitted infection~ 3. Unprotected sex with 3 or more men~ 4. Having sex for drugs, money, or shelter~ 5. Sex with a known HIV-positive man~ 6. Having a partner meeting any of the preceding criteria~* Normal menses (within 22-35 day intervals) for at least 3 cycles~* No history of alcohol abuse, heart disease, or liver disease, or any other medical condition that would interfere with the conduct of the study, in the opinion of the study investigator~* No history of loop electrosurgical excision procedure (LEEP), conization, or cryosurgery~* Normal chemistry, liver function, and complete blood count panels at screening, including:~  1. Absolute neutrophil count (ANC) ≥ 750/mm3~ 2. Hemoglobin ≥ 10.0 g/dL~ 3. Platelet count ≥ 100,000/mm3~ 4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 3 x Upper Limit Normal (ULN)~ 5. Total bilirubin ≤ 2.5 x ULN~ 6. Creatinine Clearance (CrCl) ≥ 60 mL/min as estimated by the Cockcroft-Gault equation~* Negative hepatitis B surface antigen (HBsAg)~* No signs or symptoms of orthostasis~* No signs or symptoms of vaginal infection or genital ulcer disease at screening or untreated vaginal infection in the last 30 days~* Not receiving concurrent medications that interact with maraviroc (MVC) or any antiretrovirals (such as tenofovir/ emtricitabine \[Truvada®\]) for the purpose of HIV prevention~* Willing to use condoms for the duration of the study and abstain from sexual intercourse for 48 hours before each genital tract sampling~Exclusion Criteria:~* Male sex (defined as sex at birth)~* Pregnant or breastfeeding~* Current use of systemic hormonal contraception~* Symptomatic vaginal infection or genital ulcer disease at screening or treatment for vaginal infection in the last two weeks~* Active malignancy for which the participant is undergoing evaluation and/or treatment~* Immunosuppressive medications (i.e, systemic steroids)~* Any surgery in the preceding 2 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Truvada qd (Type: EXPERIMENTAL): Women will be assigned at random Truvada 1 tablet PO daily
- Maraviroc 300 qd (Type: EXPERIMENTAL): Women will be assigned at random Maraviroc 300 mg PO daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tumor Hypoxia With HX4 PET in Several Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological/cytological confirmed carcinoma of de esophagus, rectum or prostate or radiological suspicion for Grade IV glioma (primary brain tumor) or brain metastases~* WHO performance status 0 to 2.~* Adequate renal function (calculated creatinine clearance at least 60 ml/min).~* The patient is willing and capable to comply with study procedures~* 18 years or older~* Have given written informed consent before patient registration~Exclusion Criteria:~* Recent (\< 3 months) myocardial infarction~* Pregnant or breast feeding and willing to take adequate contraceptive measures during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [18F]HX4 PET imaging (Type: EXPERIMENTAL): Injection with the hypoxia tracer \[18F\]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Linaclotide to Senna for CIC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Males and females 18 - 70 years of age. Diagnosed with CIC according to Rome III criteria. Coherent and mentally competent patient to understand and consent for the trial Unremarkable colonoscopy done in past 5 years~Exclusion Criteria:~Significant diarrhea (defined as loose or watery stool and or more than three bowel movements daily associated with urgency more than 25% of the days in preceding 3 months) Untreated hypothyroidism Organic or structural disease as the cause of patient's symptoms (stricture or tumor) Diseases that affect bowel transit time (Gastroparesis, short bowel syndrome) Evidence of cathartic colon History of alcohol, laxative abuse or illicit drug use Pregnant or lactating women Planning pregnancy or become pregnant during study period Concomitant use of any medication that could alter gastrointestinal motility (Calcium channel blockers, Narcotics, anticholinergics, calcium and aluminium containing antacids, phenothiazines, ferrous sulfate)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Senna (Type: ACTIVE_COMPARATOR): 1 capsule (50 mg) Senna daily for 12 weeks
- Linzess (Type: ACTIVE_COMPARATOR): 1 capsule (145 mcg) once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues